MetaCap

vTv Therapeutics Inc. Class A (VTVT)

NASDAQ: VTVTHealth CareBiotechnology: Pharmaceutical PreparationsUSD

15.51-0.85 (-5.20%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

VTVT stock chart

Technical analysis

Key statistics

All statistics
Market cap
$62.22M
EPS (TTM)
-$0.44
52-week range
15.47 – 44.00
Day range
15.47 – 16.47
Volume / Avg
10.59K / 33.07K
Beta
—

52-week range

$15.47$44.00

VTVT stock today

Shares of vTv Therapeutics (VTVT) finished lower on Nov 20 at $15.51, a drop of 5.20% or $0.85 per share, versus the S&P 500's 3.70% decline. Trading was light, with 10.59K shares changing hands, about 32% of the average daily volume. At this level, VTVT sits near the bottom of its 52-week range of $15.47 to $44.00: 64.8% below the high, set on Jan 6, 2026 and 0.3% above the low.

VTVT is down 61.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 47.5%. vTv Therapeutics has posted a net loss over the last twelve months (EPS of -$0.44), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About vTv Therapeutics

Company profile

vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Paul J. Sekhri
Headquarters
High Point, NC
Employees
26
IPO year
2015

Financial highlights

Full financials

In fiscal 2025, vTv Therapeutics generated $0 in revenue, down 100.0% from fiscal 2024, its first annual decline since 2023. vTv Therapeutics reported a net loss of $27.0 million, compared with a loss of $18.5 million a year earlier.

vTv Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$0$1.02M$0$2.02M$4.00M
Growth-100.00%—-100.00%-49.61%-37.56%
Net income$-26.97M$-18.46M$-20.25M$-19.16M$-12.99M
EPS (diluted)—————

Analyst forecast

Forecast

Consensus (6 analysts)

strong_buy

Avg. price target

$56.00+261.06%

  • Strong buy 0
  • Buy 6
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $42.00High $67.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-1.08 vs $-1.07
Surprise
-0.93%

VTVT news

All VTVT news

vTv Therapeutics peers

Health Care sector
VTVT peer companies
CompanyPrice% ChgMarket capCompare
FBIOFortress Biotech Inc.1.90+7.34%$64.11Mvs VTVT
RANIRani Therapeutics Holdings Inc. Class A0.5111-11.97%$59.03Mvs VTVT
GOSSGossamer Bio Inc.10.72-4.54%$65.57Mvs VTVT
PMVPPMV Pharmaceuticals Inc.0.876-33.13%$66.17Mvs VTVT
PLYXPolaryx Therapeutics Inc.1.33-11.92%$66.30Mvs VTVT
MNOVMedicinova Inc1.31+3.15%$67.11Mvs VTVT
CINGCingulate Inc.4.51-14.26%$67.48Mvs VTVT
TENXTenax Therapeutics Inc.1.25-10.07%$56.92Mvs VTVT

Indexes, lists and sector

vTv Therapeutics stock FAQ

What is vTv Therapeutics's stock price today?

VTVT last traded at $15.51 as of Nov 20, 4:00 PM EST, down 5.20% on the day. Prices are delayed at least 15 minutes.

Does vTv Therapeutics pay a dividend?

No. vTv Therapeutics does not currently pay a regular cash dividend.

Who is vTv Therapeutics's CEO?

Mr. Paul J. Sekhri is the chief executive officer of vTv Therapeutics Inc. Class A, which has about 26 employees.

Has VTVT ever split its stock?

Yes. The most recent VTVT stock split was a 1-for-40 split on Nov 21, 2023.

What is the VTVT 52-week high?

The 52-week high for VTVT is $44.00 and the 52-week low is $15.47. The stock is currently 64.8% below its high.

Compare VTVT